A second drug may join the Alzheimer’s treatment Leqembi on the market by the end of the year: Eli Lilly’s donanemab. Lilly said in a news release that it had completed its US Food and Drug Administration submission for the drug, and expects regulatory action by year’s end.
The same day Eisai’s Leqembi received full U.S. approval, Medicare officials said the government health program for the elderly will pay for it. But that doesn’t mean patients will be able to get the $26,500-a-year treatment quickly. Doctors at top medical centers said they’re still trying to coordinate required testing, reimbursement and a real-world monitoring system of patients’ side effects and cognitive status.
(CNN) The full approval this month of the Alzheimer’s drug Leqembi marked a historic shift in the treatment of the disease: For the first time, doctors have<a class="excerpt-read-more" href="https://whdh.com/news/second-alzheimers-drug-to-slow-diseases-progression-may-be-approved-in-the-us-this-year/">Read More</a>
Second Alzheimer s drug to slow disease s progression may be approved in the US this year | Health wsiltv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wsiltv.com Daily Mail and Mail on Sunday newspapers.